CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:
Net product sales	$ 1,425,839	$ 858,093	$ 44,686
Sanofi collaboration revenue	430,111	423,814	326,609
Bayer HealthCare collaboration revenue	220,289	70,099	43,072
Technology licensing and other revenue	28,506	26,471	31,457
Total revenues	2,104,745	1,378,477	445,824
Expenses:
Research and development	859,947	625,554	529,506
Selling, general, and administrative	329,415	210,755	117,261
Cost of goods sold	118,048	83,927	4,216
Cost of collaboration manufacturing	37,307	528	0
Total expenses	1,344,717	920,764	650,983
Income (loss) from operations	760,028	457,713	(205,159)
Other income (expense):
Investment (expense) income	(231)	2,012	3,549
Interest expense	(46,437)	(45,304)	(21,282)
Total other income (expense)	(46,668)	(43,292)	(17,733)
Income (loss) before income taxes	713,360	414,421	(222,892)
Income tax (expense) benefit	(288,998)	335,848	1,132
Net income (loss)	424,362	750,269	(221,760)
Net income (loss) per share - basic	$ 4.33	$ 7.92	$ (2.45)
Net income (loss) per share - diluted	$ 3.81	$ 6.75	$ (2.45)
Weighted average shares outstanding - basic	97,917	94,685	90,610
Weighted average shares outstanding - diluted	111,290	115,382	90,610
Statements of Comprehensive Income (Loss)
Net income (loss)	424,362	750,269	(221,760)
Other comprehensive income (loss):
Unrealized (loss) gain on marketable securities, net of tax	(22)	696	629
Comprehensive income (loss)	$ 424,340	$ 750,965	$ (221,131)